Real-time Estimate
Cboe BZX
12:32:10 2024-06-03 pm EDT
|
5-day change
|
1st Jan Change
|
1.725
USD
|
+1.47%
|
|
-3.91%
|
+10.97%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
377.6
|
302.8
|
282.5
|
105.7
|
103.8
|
132.5
|
-
|
-
|
Enterprise Value (EV)
1 |
189.1
|
-13.35
|
282.5
|
105.7
|
103.8
|
132.5
|
132.5
|
132.5
|
P/E ratio
|
-3.68
x
|
-9.23
x
|
-3.33
x
|
-1.06
x
|
-155
x
|
-12
x
|
-3.6
x
|
-2.09
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.57
x
|
3.02
x
|
4.06
x
|
1.99
x
|
1.03
x
|
1.28
x
|
1.74
x
|
3.05
x
|
EV / Revenue
|
6.57
x
|
3.02
x
|
4.06
x
|
1.99
x
|
1.03
x
|
1.28
x
|
1.74
x
|
3.05
x
|
EV / EBITDA
|
-3.49
x
|
-6.58
x
|
-3.48
x
|
-
|
-
|
-3.49
x
|
-
|
-
|
EV / FCF
|
-2.62
x
|
-
|
-2.34
x
|
-0.94
x
|
-
|
-3.84
x
|
-3.78
x
|
-3.01
x
|
FCF Yield
|
-38.1%
|
-
|
-42.7%
|
-106%
|
-
|
-26%
|
-26.4%
|
-33.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
45,434
|
46,224
|
65,249
|
66,084
|
66,989
|
77,919
|
-
|
-
|
Reference price
2 |
8.310
|
6.550
|
4.330
|
1.600
|
1.550
|
1.700
|
1.700
|
1.700
|
Announcement Date
|
2/27/20
|
2/24/21
|
3/1/22
|
3/27/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
57.49
|
100.4
|
69.57
|
53.16
|
101.2
|
103.2
|
76.06
|
43.4
|
EBITDA
1 |
-108.3
|
-46.03
|
-81.08
|
-
|
-
|
-38
|
-
|
-
|
EBIT
1 |
-110.9
|
-48.6
|
-83.78
|
-101.3
|
-6.484
|
-20.58
|
-59.84
|
-88.02
|
Operating Margin
|
-192.9%
|
-48.43%
|
-120.42%
|
-190.61%
|
-6.41%
|
-19.94%
|
-78.67%
|
-202.82%
|
Earnings before Tax (EBT)
1 |
-102.7
|
-46.8
|
-83.61
|
-99.32
|
3.323
|
-11.95
|
-49.96
|
-85.59
|
Net income
1 |
-102.2
|
-32.88
|
-83.61
|
-99.32
|
-0.569
|
-12.1
|
-49.97
|
-85.59
|
Net margin
|
-177.84%
|
-32.77%
|
-120.17%
|
-186.82%
|
-0.56%
|
-11.73%
|
-65.7%
|
-197.22%
|
EPS
2 |
-2.260
|
-0.7100
|
-1.300
|
-1.510
|
-0.0100
|
-0.1416
|
-0.4726
|
-0.8133
|
Free Cash Flow
1 |
-144
|
-
|
-120.6
|
-112.5
|
-
|
-34.5
|
-35
|
-44
|
FCF margin
|
-250.44%
|
-
|
-173.4%
|
-211.67%
|
-
|
-33.44%
|
-46.02%
|
-101.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/24/21
|
3/1/22
|
3/27/23
|
3/11/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
19.73
|
17.14
|
18.16
|
16.92
|
0.946
|
23.5
|
24.72
|
26.38
|
26.61
|
41.46
|
19.99
|
21.16
|
34.95
|
15.83
|
15.17
|
EBITDA
1 |
-
|
-23.36
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
12.09
|
-12
|
-16
|
-21
|
-
|
-
|
EBIT
1 |
-26.31
|
-23.97
|
-24.74
|
-23.94
|
-28.68
|
-5.653
|
-3.348
|
3.123
|
-0.606
|
11.66
|
-6.842
|
-7.908
|
-11.52
|
-8.875
|
-9.5
|
Operating Margin
|
-133.36%
|
-139.86%
|
-136.21%
|
-141.54%
|
-3,032.24%
|
-24.06%
|
-13.54%
|
11.84%
|
-2.28%
|
28.11%
|
-34.22%
|
-37.37%
|
-32.95%
|
-56.05%
|
-62.64%
|
Earnings before Tax (EBT)
1 |
-26.23
|
-23.88
|
-24.18
|
-23.3
|
-27.95
|
-3.311
|
-1.087
|
5.815
|
1.906
|
13.84
|
-5.835
|
-7.006
|
-10.76
|
-7.834
|
-8.662
|
Net income
1 |
-26.23
|
-23.88
|
-24.18
|
-23.3
|
-27.95
|
-3.311
|
-1.087
|
2.992
|
0.837
|
13.79
|
-5.944
|
-7.109
|
-10.76
|
-7.834
|
-8.662
|
Net margin
|
-132.95%
|
-139.38%
|
-133.14%
|
-137.72%
|
-2,954.76%
|
-14.09%
|
-4.4%
|
11.34%
|
3.15%
|
33.26%
|
-29.73%
|
-33.6%
|
-30.77%
|
-49.47%
|
-57.11%
|
EPS
2 |
-0.4000
|
-0.3700
|
-0.3700
|
-0.3500
|
-0.4200
|
-0.0500
|
-0.0200
|
0.0400
|
0.0100
|
0.1700
|
-0.0715
|
-0.0825
|
-0.1241
|
-0.0950
|
-0.1050
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/1/22
|
5/5/22
|
8/4/22
|
11/8/22
|
3/27/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/11/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
188
|
316
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-144
|
-
|
-121
|
-113
|
-
|
-34.5
|
-35
|
-44
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-120%
|
-
|
-
|
-
|
-308%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-24%
|
-33.1%
|
-
|
-18.4%
|
-33.6%
|
-
|
Assets
1 |
-
|
-
|
349
|
300.2
|
-
|
65.82
|
148.9
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
3.5
|
-
|
1.61
|
1.74
|
-
|
-
|
-
|
-
|
Capex / Sales
|
6.08%
|
-
|
2.31%
|
3.27%
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/24/21
|
3/1/22
|
3/27/23
|
3/11/24
|
-
|
-
|
-
|
Average target price
5.318
USD Spread / Average Target +212.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.68% | 132M | | +11.60% | 106B | | -4.68% | 24.28B | | -0.29% | 21.96B | | -8.07% | 18.16B | | -42.12% | 16.37B | | -17.47% | 15.56B | | +2.77% | 13.63B | | +34.58% | 12.27B | | +77.64% | 8.87B |
Bio Therapeutic Drugs
|